Genitourinary System Carcinoma — Research

Genitourinary System Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Exact query	Computed	Source
All time	… → 2026-09-11	`("Genitourinary System Carcinoma"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	`("Genitourinary System Carcinoma"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	`("Genitourinary System Carcinoma"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (157)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 51–75 of 157 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations.
· J Clin Oncol · 2025 · PMID 39413348 · validated civic_curation pubmed
Complete loss of STAG2 expression is an indicator of good prognosis in patients with bladder cancer.
· Tumour Biol · 2016 · PMID 26838030 · validated civic_curation pubmed
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
· Clin Cancer Res · 2013 · PMID 23881929 · validated civic_curation pubmed
A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring HRAS Mutations.